CompletedPhase 2NCT02556437
Efficacy and Safety of HyQvia (Immunoglobulin 10% With Recombinant Hyaluronidase) in Multifocal Motor Neuropathy (MMN)
Studying Multifocal motor neuropathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Johannes Jakobsen
- Principal Investigator
- Johannes Jakobsen, DMScNeuroscience Center, Rigshospitalet
- Intervention
- HyQvia(drug)
- Enrollment
- 18 target
- Eligibility
- 18-90 years · All sexes
- Timeline
- 2016 – 2018
Study locations (2)
- Department of Neurology, Aarhus University Hospital, Aarhus C, Denmark
- Department of Neurology, Rigshospitalet, Copenhagen, Denmark
Collaborators
Baxter Healthcare Corporation
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02556437 on ClinicalTrials.govOther trials for Multifocal motor neuropathy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT06742190A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathyargenx
- RECRUITINGPHASE2NCT06537999A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor NeuropathyDianthus Therapeutics
- ACTIVE NOT RECRUITINGNCT05988073A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathyargenx
- ACTIVE NOT RECRUITINGPHASE2NCT05405361A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathyargenx